A Retrospective Study on the Treatment of Intermediate and Advanced Liver Cancer.

This study looks at how well a treatment called **TACE** works for people with serious liver cancer. TACE stands for Transarterial Chemoembolization, a procedure that delivers chemotherapy directly to the liver. The study compares TACE combined with two other treatments, **immunotherapy** and **targeted therapy**, to see which is better. Immunotherapy helps the body's immune system fight cancer, and targeted therapy uses drugs to attack cancer cells without harming normal cells.

Researchers want to find out how safe and effective these treatments are, and why some patients might respond better than others. They will also create a system to predict how well patients might do with these treatments.

• Participants must be at least 18 years old with certain liver cancer stages and good health.
• Those with other serious health issues or who have had other significant cancers recently are not eligible.
• Being part of the study helps doctors understand more about how to treat liver cancer.